Wells Fargo & Company Apellis Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 160,228 shares of APLS stock, worth $5.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
160,228
Previous 145,035
10.48%
Holding current value
$5.69 Million
Previous $8.53 Million
27.91%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
113MCall Options Held
5.21MPut Options Held
691K-
Wellington Management Group LLP Boston, MA16.4MShares$582 Million0.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.6MShares$412 Million15.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$395 Million5.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$349 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$206 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.9B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...